Atlas Trials

XIANG YANQUN

6 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch XIANG YANQUN

RecordFirmDate
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial (NCT06438627)XIANG YANQUN2024-05-30
Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy (NCT06414577)XIANG YANQUN2024-05-22
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. (NCT06383780)XIANG YANQUN2024-05-15
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma (NCT05869227)XIANG YANQUN2023-04-28
PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma (NCT05229315)XIANG YANQUN2022-03-12
Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study (NCT04872582)XIANG YANQUN2021-07-29

Track XIANG YANQUN automatically

Every clearance here is in the API, with alerts when new ones post.